Table 4.
Performance of previously identified African signatures in the diagnosis of TB disease in the Norwegian cohort and the combined Norwegian and South African cohort.
| Biosignature | AUC (95% CI) | Sens (95%CI) | Spec (95%CI) | Sens (95%CI) | Spec (95%CI) | PPV (95%CI) | NPV (95%CI) |
|---|---|---|---|---|---|---|---|
| Accuracy in training set | Accuracy in test set or after leave-one-out cross-validation | ||||||
| NORWEGIAN COHORT | |||||||
| *Chegou et al. (9) (CRP, SAA, IFN-γ, IP-10, CFH, ApoA-1) |
0.84 (0.75–0.93) |
69.9% (58.8–79.5) |
88.2% (63.6–98.5) |
67.5% (56.3–77.4) |
64.7% (38.3–85.8) |
90.3% (82.8–94.8) |
30% (20.3–39.4) |
| Jacobs et al. (10) (CRP, SAP, NCAM-1, Ferritin, I-309, GDF-15) | 0.94 (0.90–0.99) |
81.2% (71.2–88.8) |
94.7% (74–99.9) |
78.8% (68.6–86.9) |
89.5% (66.9–98.7) |
97.1% (89.9–99.2) |
48.6% (37.9–59.4) |
| NORWEGIAN AND SOUTH AFRICAN COHORTS COMBINED | |||||||
| Training set (n = 105; n = 56 TB, n = 49 ORD) | Test set (n = 43; n = 22 TB, n = 21 ORD) | ||||||
| *Chegou et al. (9) (CRP, SAA, IFN-γ, IP-10, CFH, ApoA-1) | 0.85 (0.77–0.92) |
75% (61.6–85.6) |
77.6% (63.4–88.2) |
63.6% (40.7–82.8) |
80.9% (58.1–94.5) |
77.8% (57.8–89.9) |
68% (54.1–79.3) |
| Jacobs et al. (10) (CRP, SAP, NCAM-1, Ferritin, I-309, GDF-15) | 0.87 (0.80–0.94) |
75% (61.6–85.6) |
85.7% (72.8–94.1) |
63.6% (40.7–82.8) |
76.2% (52.8–91.7) |
73.7% (55–86.5) |
66.7% (52.3–78.5) |
Previously published biosignatures; a serum biosignature (9), and a plasma biosignature (10), were evaluated in the Norwegian cohort and in Norwegian and South African cohorts combined.
*
One of the key biomarkers in the 7-marker serum biosignature (transthyretin) was unavailable, hence data shown is for performance of the remaining 6 analytes in the signature.
AUC, Area under the ROC curve; Sens, sensitivity; Spec, specificity; PPV, Positive predictive value; NPV, Negative predictive value; CI, Confidence Interval.